Avid Bioservices Inc (CDMO)

[BioBS2012]

Pancreatic cancer trial - Monday morning quarterbacking

First of all to all those who call the PC trial a failure - what is your definition of failure? For me failure would be reaching a dead-end for that specific indication. If Pphm were to drop further development of Bavi in PC, then yes the Phase II trial was a failure. However, from everything they have stated thus far this is not the case. In fact I sense some excitement in how the study turned out.

Look at it this way - given the ECOG of the patientswhat was the best MOS that might have been achieved? Lets assume it was 2 months better then control (5.2 vs 7.2 = 38%) well, just a few weeks back Abraxane showed an increase of 2 months over SOC in a Phase III and will likely become the new SOC. So even with a "successful trial" PPHM would be doing what they are now doing, which is trying to determine the best path forward in this indication - do you test Bavi in healthier patients with existing SOC Or do you go with Bavi+Abraxane? Do you do another small Phase II or run a gold standard double blind Phase II that could become a basis for approval? Again, these kind of questions don't arise if a trial is a Failure.

In hind sight it is good that the results are what they are. They now have a better opportunity to chart the best way forward in PC especially with what they have learned and what the new landscape looks like.

GLTA